Table 3.
Selected patient characteristics of 91 subjects with osteoporosis and BRONJ
| Total cohort | Excluding subjects with missing data |
|||
|---|---|---|---|---|
| Characteristics | N (%) or Median (IQR) |
N (%) or Median (IQR) |
||
| Gender | ||||
| male | 5 | (5.4%) | 5 | (5.4%) |
| female | 86 | (94.5%) | 86 | (94.5%) |
| Median age at presentation, years | 71.0 | (19.0) | 71.0 | (19.0) |
| Bisphosphonate type* | ||||
| alendronate | 75 | (77.3%) | 75 | (82.4%) |
| ibandronate | 5 | (5.2%) | 5 | (5.5%) |
| risedronate | 4 | (4.1%) | 4 | (4.4%) |
| pamidronate | 4 | (4.1%) | 4 | (4.4%) |
| zoledronic | 3 | (3.1%) | 3 | (3.3%) |
| missing | 6 | (6.2%) | 0 | (0.0%) |
| Median duration BP use (months) | 60.0 | (78.0) | 60.0 | (78.0) |
| Area of mouth affected by ONJ | ||||
| maxilla | 34 | (37.3%) | 34 | (37.5%) |
| mandible | 53 | (58.2%) | 53 | (60.2%) |
| both | 2 | (2.2%) | 2 | (2.3%) |
| missing | 2 | (2.2%) | ||
| Pain at ONJ Site | ||||
| yes | 28 | (30.8%) | 28 | (65.1%) |
| no | 15 | (16.5%) | 15 | (34.9%) |
| missing | 48 | (52.7%) | ||
| Highest ONJ stage† | ||||
| stage 0 | 0 | (0.0%) | 0 | (0.0%) |
| stage 1 | 7 | (7.6%) | 7 | (38.9%) |
| stage 2 | 8 | (8.8%) | 8 | (44.4%) |
| stage 3 | 3 | (3.3%) | 3 | (16.7%) |
| missing | 73 | (80.2%) | ||
| Extraction or Implant | ||||
| yes | 38 | (41.8%) | 38 | (71.7%) |
| no | 15 | (16.5%) | 15 | (28.3%) |
| missing | 38 | (41.8%) | ||
| Treatment Type | ||||
| surgical | 31 | (34.1%) | 31 | (68.9%) |
| non-Surgical | 14 | (15.4%) | 14 | (31.1%) |
| missing | 46 | (50.5%) | ||
| ONJ Improved | ||||
| yes | 32 | (35.1%) | 32 | (80.0%) |
| no | 8 | (8.8%) | 8 | (20.0%) |
| missing | 51 | (56.0%) | 0 | (0.0%) |
*
Totals more than 91; some patients on more than 1 bisphosphonate.
†
Data from Table 1 only
Abbreviations: ONJ, osteonecrosis of the jaw; IQR; Interquartile range